Wainwright targets Prelude Therapeutics stock at USD 8.00

Published on 10/14/2026 at 03:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Wainwright reiterated Buy on October 13, 2026 with a USD 8.00 target. Prelude Therapeutics stock enters a Phase 1 trial in fourth-quarter 2026.

Analyst target and trial timeline

H.C. Wainwright reiterated a Buy rating on October 13, 2026.
Prelude expects Phase 1 enrollment in the fourth quarter of 2026.
The Lilly collaboration evaluates PRT13722 in a Phase 1 breast cancer study.

PRLD, US74065P1012, Illustration mit AI erstellt.

H.C. Wainwright reiterated a Buy rating on Prelude Therapeutics stock and set a USD 8.00 price target on October 13, 2026, according to Markets Insider. The analyst action followed Prelude's clinical trial collaboration and supply agreement with Eli Lilly.

Lilly supplies two medicines

According to GlobeNewswire, the October 13, 2026 agreement covers Prelude's oral KAT6A degrader PRT13722 and Lilly's abemaciclib and imlunestrant. The Phase 1 study will evaluate combinations in patients with hormone receptor-positive and HER2-negative breast cancer.

The U.S. Food and Drug Administration recently cleared Prelude to proceed under its Investigational New Drug application. The company expects enrollment to begin in the fourth quarter of 2026, starting with monotherapy dose escalation before combination cohorts.

What does the collaboration change?

The agreement gives Prelude access to established Lilly medicines while keeping full global development and commercial rights to PRT13722. That structure makes the trial a defined clinical milestone rather than a commercial launch, because the program remains in Phase 1 and its efficacy and safety still require human testing.

The company describes preclinical synergy with endocrine therapy, CDK4/6 inhibitors and PI3K inhibitors in breast cancer models. It also reported durable complete tumor regressions in cell-derived and patient-derived xenograft models, but those findings remain preclinical and do not establish clinical benefit.

Three dated development steps

On August 11, 2026, Prelude Therapeutics published its second-quarter 2026 financial results and corporate update. The company said its PRT13722 Phase 1 study was expected to begin enrollment in the fourth quarter of 2026.

On September 10, 2026, Prelude Therapeutics announced FDA clearance of the Investigational New Drug application for PRT13722. On October 13, 2026, GlobeNewswire reported the Lilly collaboration.

Dates and market context

The next substantiated development window is the fourth quarter of 2026, when Prelude expects patient enrollment to start. The company is listed on Nasdaq under PRLD, and its market capitalization was USD 202.7 million as of October 13, 2026.

On the same date, the Nasdaq 52-week range was USD 1.16 to USD 6.83. The range places the USD 8.00 analyst target above the reported yearly high, while the clinical program remains dependent on future trial execution and human data.